Cobicistat has little impact on CYP2D6 and CYP2B6
1 May 2011. Related: Conference reports, Antiretrovirals.
Antiretrovirals
Atazanavir levels indicate need for higher dose during pregnancy
1 May 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Etravirine lowers levels of maraviroc given at 300 or 600 mg twice daily
1 May 2011. Related: Conference reports, Antiretrovirals.
Once-daily 150-mg maraviroc explored in people taking atazanavir/ritonavir
1 May 2011. Related: Conference reports, Antiretrovirals.
Lopinavir troughs lower in children on once-daily dose with efavirenz
1 May 2011. Related: Conference reports, Antiretrovirals, Paediatric care.
Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily
1 May 2011. Related: Conference reports, Antiretrovirals, Treatment strategies.
Rapid report: state of HCV policy, treatment, access
1 May 2011. Related: Conference reports, Antiretrovirals.
When to start ART in patients co-infected with TB: results from two trials presented at CROI
1 May 2011. Related: Conference reports, Antiretrovirals, TB coinfection.
Inflammation and intervention: how does HIV cause AIDS and how does it cause disease despite ART
1 May 2011. Related: Conference reports, Antiretrovirals.
New antiretrovirals: dolutegravir, entry inhibitor (BMS-663068) and tenofovir pro-drug (GS-7340)
1 April 2011. Related: Conference reports, Antiretrovirals.
Immune-based treatment increases HIV-resistant CD4 cells in phase 1 study
1 April 2011. Related: Conference reports, Antiretrovirals.
Antiretroviral prevention: oral PrEP, gels and treatment studies
1 April 2011. Related: Conference reports, Antiretrovirals.
Further efficacy analyses from the iPrEx study
1 April 2011. Related: Conference reports, Antiretrovirals.
Topical gels as PEP and PrEP: animal and human studies
1 April 2011. Related: Conference reports, Antiretrovirals.
Maternal risk following short course HAART
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Pre-term delivery and HAART
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
HAART more effective than AZT monotherapy in the Botswana PMTCT programme
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
Lopinavir/r monotherapy for PMTCT
1 April 2011. Related: Conference reports, Antiretrovirals, Pregnancy.
First results from telaprevir in HIV/HCV coinfection
1 April 2011. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.
London HIV Consortium issues new guidelines for ARV prescribing (2011)
1 April 2011. Related: Antiretrovirals, Guidelines.
EMA issue restricted indication for d4T (stavudine)
1 April 2011. Related: Antiretrovirals.
Changes to starting dose of saquinavir in naive patients
1 April 2011. Related: Antiretrovirals.
FDA approve nevirapine XR
1 April 2011. Related: Antiretrovirals.
Lopinavir/r oral solution
1 April 2011. Related: Antiretrovirals.
Atazanavir use during pregnancy
1 April 2011. Related: Antiretrovirals, Pregnancy.
Nelfinavir interaction with warfarin
1 April 2011. Related: Antiretrovirals.
Lopinavir/ritonavir: women versus men
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
Quality of life in the GRACE study
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
Antiretroviral pharmacokinetics in women with undetectable viral load
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health.
No association between bone mineral density and lipodystrophy in women receiving antiretroviral therapy
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Weight, diabetes, metabolic complications.
The impact of antiretroviral treatment on fertility intentions in South Africa
1 February 2011. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
US adult treatment guidelines updated January 2011
1 February 2011. Related: Antiretrovirals, Guidelines.
FDA safety updates to antiretroviral labels
1 February 2011. Related: Antiretrovirals.
Darunavir once-daily indication in treatment experienced adults
1 February 2011. Related: Antiretrovirals.
Virological findings from the SARA trial ofboosted protease inhibitor monotherapy
1 December 2010. Related: Conference reports, Antiretrovirals, Treatment access, Virology.
Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART
1 December 2010. Related: Conference reports, Antiretrovirals.
Efavirenz versus nevirapine based first linetreatment in a South African cohort
1 December 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
1 December 2010. Related: Conference reports, Antiretrovirals.
Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option (2010)
1 December 2010. Related: Conference reports, Antiretrovirals, Guidelines.
Muscle weakness or pain analysed as possible raltegravir side effect
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Adding maraviroc does not boost CD4s inrandomised trial
1 December 2010. Related: Conference reports, Antiretrovirals.
Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
1 December 2010. Related: Conference reports, Antiretrovirals.
Small but higher rates of AIDS and non-AIDS complications with uncontrolled HIV despite CD4s over 350
1 December 2010. Related: Conference reports, Antiretrovirals.
Once-daily raltegravir fails to demonstrate non-inferiority compared to twice-dailydosing in phase 3 treatment naive study
1 December 2010. Related: Antiretrovirals.
FDA safety updates to antiretroviral labels
1 December 2010. Related: Antiretrovirals, Side effects.
Update to US saquinavir label
1 December 2010. Related: Antiretrovirals, Side effects.
Raltegravir pharmacokinetics inpregnancy
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Low birth weight associated with HAART in pregnancy in Zambia
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Bilirubin levels in infants following in utero atazanavir exposure compared to exposure to other antiretrovirals
1 October 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
Novel mutations and shifting susceptibility to darunavir and tipranavir
1 October 2010. Related: Conference reports, Antiretrovirals, Drug resistance.
Four-drug single-pill antiretroviral equivalent to Atripla at 48 weeks
1 October 2010. Related: Conference reports, Antiretrovirals.
High rates of bone loss and progression with HIV in longitudinal study
1 October 2010. Related: Conference reports, Antiretrovirals, Side effects.
Spray-dried nanoparticle formulation of efavirenz
1 October 2010. Related: Conference reports, Antiretrovirals.
Switching boosted-PIs to raltegravir
1 October 2010. Related: Conference reports, Antiretrovirals, Treatment strategies.
Early infant diagnosis
1 October 2010. Related: Conference reports, Antiretrovirals, Paediatric care, Diagnostics.
Efavirenz-based regimens among womenof reproductive age receiving ART in Johannesburg
1 October 2010. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
START study given green light for full study
1 October 2010. Related: Antiretrovirals.
Saquinavir prolongation of QT interval: Rocheissue Dear Doctor letter
1 October 2010. Related: Antiretrovirals.
Development of chronic kidney disease and antiretroviral use in EuroSIDA cohortsince 2004
1 October 2010. Related: Antiretrovirals, Side effects.
Rilpivirine (TMC-278) vs efavirenz in treatment-naive patients: phase 3 results
26 August 2010. Related: Conference reports, Antiretrovirals.
Once-daily nevirapine extended release (XR) is non-inferior to current formulation
26 August 2010. Related: Conference reports, Antiretrovirals.
GSK572 (dolutegravir): second-generation integrase inhibitor
26 August 2010. Related: Conference reports, Antiretrovirals.
TBR-652: early results for CCR5 inhibitor
26 August 2010. Related: Conference reports, Antiretrovirals.
Atazanavir/r plus maraviroc or tenofovir/FTC in treatment-naive patients
26 August 2010. Related: Conference reports, Antiretrovirals.